FDA clears absorbable soft-tissue marker from Augmenix

01/29/2013 | AuntMinnie.com (free registration)

The FDA has given Augmenix 510(k) clearance to market TraceIT, an injectable synthetic hydrogel used to mark soft tissue radiographically before surgery. The technology, which can be viewed through MRI and other ultrasound modalities, is designed to help streamline image fusion and enhance soft-tissue alignment.

View Full Article in:

AuntMinnie.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA